High Dose Chemotherapy with Ifosfamide, Carboplatin, and Etoposide Followed by Autologous Stem Cell Transplantation in Breast Cancer.
- Author:
Soo Mee BANG
1
;
Se Hoon LEE
;
Eun Kyung CHO
;
Jung Ae LEE
;
Young Suk PARK
;
Dong Bok SHIN
;
Jae Hoon LEE
;
Yung Jue BANG
;
Seonyang PARK
;
Byoung Kook KIM
;
Noe Kyeong KIM
Author Information
1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea. seonpark@plaza.snu.ac.kr
- Publication Type:Original Article
- Keywords:
High dose chemotherapy;
Autologous stem cell transplantation;
Breast neoplasm
- MeSH:
Breast Neoplasms*;
Breast*;
Carboplatin*;
Colony-Stimulating Factors;
Cyclophosphamide;
Drug Therapy*;
Drug Therapy, Combination;
Etoposide*;
Humans;
Ice;
Ifosfamide*;
Lymph Nodes;
Platelet Transfusion;
Stem Cell Transplantation*;
Stem Cells*
- From:Journal of the Korean Cancer Association
2000;32(6):1059-1066
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To establish the feasibility of high dose ifosfamide, carboplatin, and etoposide (ICE) chemotherapy followed by autologous stem cell transplantation (ASCT) in patients with high-risk or metastatic breast cancer. MATERIALS AND METHODS: High-risk breast cancer is defined as 10 or more involved axillary lymph nodes (n=3) or stage III (n=2). Patients with metastatic cancer have relapsed diseases after curative resection (n=10) or initially metastatic lesion (n=1). Colony stimulating factor with either cyclophosphamide or combination chemotherapy was administered to mobilize the stem cells. High dose chemotherapy consisted of ifosfamide 16 g/m2, carboplatin 1.8 g/m2, and etoposide 0.75 g/m2 (dose I) and later modified to ifosfamide 12 g/m2, carboplatin 1.35 g/m2, and etoposide 1.2 g/m2 (dose II). RESULTS: The median duration of grunulocyte nadir (<500/ microliter) was 11 (10~17) days and platelet transfusion dependency (<20,000/ microliter) was 11 (7~53) days in 14 patients who achieved engraftment. One out of 5 patients with high-risk breast cancer relapsed after high dose therapy. Two patients remain disease-free at 18th and 40th months. Two among the 4 patients treated with dose I died due to treatment-related complications. The responses of metastatic diseases to ICE chemotherapy were 1 continuing CR, 1 CR, 1 PR, 4 SD and 3 PD in 10 evaluable patients. CONCLUSION: High dose ICE chemotherapy, especially dose II and ASCT were feasible in high-risk or metastatic breast cancer.
